Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.64 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043160 | 1.00 | EPHX1 (0.64) | EPHX1TRPM8TRPA1TRPV1CYP3A4 | |
| SCHEMBL21350183 | 1.00 | EPHX1 (0.64) | EPHX1TRPM8TRPA1TRPV1CYP3A4 | |
| SCHEMBL14072926 | 0.87 | EPHX1 (0.48) | EPHX1TRPM8CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL14072930 | 0.87 | EPHX1 (0.48) | EPHX1TRPM8CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL14510042 | 0.85 | EPHX1 (0.44) | EPHX1TRPM8CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL6923690 | 0.84 | EPHX1 (0.62) | EPHX1TRPM8TRPA1TRPV1 | |
| SCHEMBL1238085 | 0.84 | EPHX1 (0.62) | EPHX1TRPM8TRPA1TRPV1 | |
| SCHEMBL1439241 | 0.84 | EPHX1 (0.62) | EPHX1TRPM8TRPA1TRPV1 | |
| SCHEMBL10034576 | 0.83 | EPHX1 (0.75) | EPHX1TRPM8TRPA1TRPV1 | |
| SCHEMBL6128506 | 0.83 | EPHX1 (0.75) | EPHX1TRPM8TRPA1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| EP-0050263-A1 | Cationic dyes, their preparation and their use in the dyeing of cationically dyeable fibres and paper | BAYER AG (DE) | 1982-04-28 | — | — | EP | claimed |
| CN-107532063-A | Methyl menthol derivative and the cooling agent composition containing it | 高砂香料工业株式会社 | 2018-01-02 | — | — | CN | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2097079-B1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER FLEMING LTD (GB) | 2012-06-27 | — | — | EP | disclosed |
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | disclosed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2147673-A1 | Modulation of prostaglandin/cyclooxygenase metabolic pathways | Hunter-Fleming Limited (GB) | 2010-01-27 | — | — | EP | disclosed |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| EP-2097079-A2 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | Hunter-Fleming Limited (GB) | 2009-09-09 | — | — | EP | disclosed |
| EP-0560613-A1 | Antimicrobial carbapenem derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0470686-A2 | (Benzhydryloxyethylpiperidyl)aliphatic acid derivatives and their use in the treatment of allergies and asthma | Sankyo Company Limited (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | EPHX1 490/4885TRPM8 3001/4885TRPA1 1640/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | EPHX1 490/4885TRPM8 3001/4885TRPA1 1640/4885 |
| US-20090259043-A1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HCRTR1, CDR2, MSR1 | EPHX1 2049/4885TRPM8 1235/4885TRPA1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.